


PROGRESS

In The Management Of Cystic Fibrosis



creon[®] 
pancreatin

RIGHT ON TARGET – RIGHT FROM THE START

Prescribing Information – Presentation: Brown-yellow capsules containing enteric coated granules of pancreatin equivalent to: 9,000 BP units of amylase, 8,000 BP units of lipase, 210 BP units of protease. Available in packs of 100. Basic NHS price £13.33. **Indication:** Pancreatic exocrine insufficiency. **Dosage and administration:** Adults and children: Initially one or two capsules with meals, then adjust according to response. The capsules can be swallowed whole, or for ease of administration they may be opened and the granules taken with fluid or soft food, but without chewing. If the granules are mixed with food, it is important that they are taken immediately, otherwise dissolution of the enteric coating may result.

Contra-indications, Warnings, etc: Contra-indications: Substitution with pancreatic enzymes is contra-indicated in the early stages of acute pancreatitis. Warnings: Use in pregnancy: There is inadequate evidence of safety in use during pregnancy. The product is of porcine origin. Rarely cases of hyper-uricosuria and hyper-uricaemia have been reported with high doses of pancreatin. Overdosage could precipitate meconium ileus equivalent. Perianal irritation could occur, and, rarely, inflammation when large doses are used. **Product Licence Number:** 5727/0001. **Name and address of Licence Holder:** Kali Chemie Pharma GmbH, Postfach 220, D-3000, Hannover 1, West Germany.

duphar

Further information is available from:
Duphar Laboratories Limited, Gaters Hill, West End, Southampton SO3 3JD. Tel: 0703 472281.

CRA4/PE1/1/89




Making sure Ventolin gets through to the younger generation



VENTODISKS

(Salbutamol BP)



Ventodisks (Salbutamol BP). **Abridged Prescribing Information** (Please refer to full data sheet before prescribing.) **Uses:** Treatment and prophylaxis of acute and chronic bronchospasm. **Dosage and administration:** *Adults:* 400 micrograms as single dose or three to four times daily. *Children:* 200 micrograms as single dose or three to four times daily. **Contra-indications:** Threatened abortion during first or second trimester. Hypersensitivity. **Precautions:** If previously effective dose lasts less than three hours, seek medical advice. Caution in patients with thyrotoxicosis. Avoid use with non-selective beta-blockers. Hypokalaemia may occur, particularly in acute severe asthma. It may be potentiated by xanthine derivatives, steroids, diuretics and hypoxia. Serum potassium levels should be monitored in such situations. **Pregnancy:** Avoid unnecessary use during early pregnancy. Only consider if expected benefit outweighs possible risks. **Lactation:** Salbutamol likely to

be secreted in breast milk. Effect on neonate unknown. Balance risks against benefits. **Side effects:** Mild tremor, headache occur rarely. Very rarely — transient muscle cramps and hypersensitivity reactions. Potentially serious hypokalaemia may result from β_2 -agonist therapy. Paradoxical bronchospasm could occur — substitute alternative therapy.

Presentation and Basic NHS cost: Pack of 14 Ventodisks each containing 8 x 200 micrograms Salbutamol BP (as sulphate) — light blue or 8 x 400 micrograms Salbutamol BP (as sulphate) — dark blue, together with a Ventolin Diskhaler. For inhalation. £7.11 and £12.02. Refill pack of 14 x 8 Ventodisks only. 200 micrograms, £6.54; 400 micrograms, £11.45.

Product licence numbers: Ventodisks 200 micrograms 0045/0134, Ventodisks 400 micrograms 0045/0135.



ALLEN & HANBURY'S

Further information is available on request from: Allen & Hanburys Limited, Stockley Park West, Uxbridge, Middlesex UB11 1BT
Ventodisks should only be used with a Ventolin Diskhaler. Diskhaler, Ventodisks and Ventolin are trade marks

PRESCRIBING INFORMATION **Presentation** TILADE Mint is a metered dose pressurised aerosol inhaler which delivers 56 puffs, each containing 2mg Nedocromil sodium. **Indications** TILADE Mint is indicated for the preventive treatment of reversible obstructive airways disease, including asthma and asthmatic bronchitis. **Dosage and Administration** Adults and children over 12 years of age: 2 puffs (4mg Nedocromil sodium) to be inhaled twice daily. If necessary, dosage may be increased to 2 puffs four times daily.

Children under 12 years of age: it is recommended that TILADE Mint should not be used since it is still under investigation in this age group. TILADE Mint is intended for regular daily usage and should not be used for relief of symptoms in an acute attack. **Side effects, precautions and contraindications** Few side effects have been reported, principally headache and nausea. The mint flavour has been added to mask any bitter taste of the drug. Caution should be exercised in the use of TILADE Mint in pregnant or lactating

women. There are no specific contraindications. **Basic NHS Cost** 2 x 56 actuations £17.76. **PL Number** 0113/0140. Further information is available on request. © Registered Trade Mark of the Manufacturer. Fisons plc - Pharmaceutical Division, 12 Derby Road, Loughborough, Leicestershire LE11 1 QBB

NEW
MINT TASTE

FISONS
Pharmaceuticals



ASTHMA

TILADE[®] MINT
Nedocromil sodium



FOR THE PREVENTIVE TREATMENT OF ALL NON-ASTEROID

What would you feed her if she were born premature?

The Challenge

What to feed the preterm, low birthweight infant is one of the biggest challenges in neonatology. The preterm infant may have a five-fold range of body weight and a wide range of level of immaturity. But advances over the last decade have made important contributions to the understanding of their special nutritional needs.¹

Clinical data shows an excellent performance from Milupa Prematil^{3, 4} and low birthweight formulae in general.^{5, 6} Babies fed preterm formulae grow faster and better than those fed EBM or standard formulae.

Milupa Prematil has been developed to meet the latest ESPGAN guidelines² for preterm formulae and translate them into action.

Milupa Prematil is being used in over 60 Special Care Units throughout the country.

Milupa Prematil → Proven performance in clinical

★ Prematend includes 30% MCT for high fat absorption (87%) ensuring energy retention and enhanced protein utilization.

★ Excellent protein utilization (90%) promotes growth without metabolic overload.

★ Good tolerance and nutritional balance ensures supplementation is rarely required.

★ No added iron allows greater flexibility in the management of iron status.†


milupa **Prematil®**

From **milupa Prematil** to **Aptamil** an assured path to normal formula feeding.

References

1. Committee on Nutrition of the Preterm Infant. European Society of Paediatric Gastroenterology and Nutrition. Nutrition and feeding of preterm infants. Oxford: Blackwell, 1987.
2. ESPGAN Committee on Nutrition of the Preterm Infant. Acta Paediatr Scand. 1987 Suppl. 336: 1-14.
3. Salle, B., Putet G. Service de Néonatalogie de L'Hôpital Universitaire Edouard Herriot, Lyons, France. Senterre J., Rigo J., Service de Néonatalogie de L'Hôpital Universitaire de Bavière, Liege, Belgium (data on file).
4. Miall-Allen V.M., Whitelaw A.G.L. Dept. Paediatrics and Neonatal Medicine. Hammersmith Hospital, London (data on file).
5. Brooke, O.G. et al. Archives of Disease in Childhood 1982, 57, 898-904.
6. Lucas, A. et al. Archives of Disease in Childhood, 1984, 59, 722-730.

† Iron supplementation should therefore be considered from around 6 weeks.



Milupa Ltd., Milupa House, Uxbridge Road, Hillingdon, Uxbridge, Middlesex UB10 0NE. Tel: 081-573 9966.



Children with uncontrolled seizures can gain control of their lives

Sabril can have a dramatic effect on the lives of children with epilepsy.

Almost 50% of children with uncontrolled epilepsy who have had Sabril added to their existing therapy have shown a good to excellent

response. Some have become seizure free.⁽¹⁾

Sabril is generally well tolerated and can be administered conveniently in either single or divided daily doses.

SABRIL®
VIGABATRIN

Specific GABA-transaminase inhibition
for uncontrolled epilepsy



Merrell Dow Pharmaceuticals Limited, Lakeside House, Stockley Park, Uxbridge, Middlesex UB11 1BE
Trademarks: Merrell, Dow, Sabril.

**MERRELL
DOW**

Abridged Prescribing Information

SABRIL▼ Tablets

Presentation: White tablets with a breakline marked SABRIL, each containing 500mg vigabatrin.

Uses:

Indications: Treatment of epilepsy not controlled by other antiepileptic drugs.

Dosage and Administration: Oral administration once or twice daily added to the patient's current therapeutic regimen.

Adults: Recommended starting dose 2g/day. Increased or decreased in 0.5g or 1.0g increments depending upon clinical response and tolerability. Maximum 4g/day. There is no direct correlation between plasma concentration and efficacy.

Children: Recommended starting dose 1g/day in ages 3-9 years and 2g/day if older.

Elderly: Consider dose reduction in patients with impaired renal function.

Contra-indications, Precautions, Warnings etc

Use in pregnancy and lactation: Contra-indicated.

Precautions: Abrupt withdrawal may lead to rebound seizures. Caution in patients with history of psychosis or behavioural problems. Caution in elderly patients, particularly creatinine clearance below 60ml/min. Reduce dose and monitor closely for adverse events.

Warnings: Vigabatrin causes intramyelinic oedema in the brain white matter tracts of animals but there is no evidence of this in man. However, monitor patients for neurological changes. See the full product data sheet.

Effects on driving ability: Drowsiness has been seen and patients should be warned.

Side effects: Are mainly CNS related. Aggression and psychosis have been reported and a previous history of psychosis or a behavioural problem appears to be a predisposing factor. Other reported events: drowsiness and fatigue, dizziness, nervousness, irritability, depression, headache and less commonly confusion, memory disturbance and vision complaints; also weight gain and minor gastrointestinal side-effects. Also in children excitation and agitation. Some patients may experience an increase in seizure frequency with vigabatrin, particularly those with myoclonic seizures. Tests have not revealed evidence of neurotoxicity in humans. Lab data do not indicate renal or hepatic toxicity. Decreases in SGOT and SGPT have been observed. Chronic treatment may lead to a slight decrease in haemoglobin.

Drug Interactions: Are unlikely. A gradual reduction of about 20% in plasma phenytoin concentration has been observed. No clinically significant interactions with carbamazepine, phenobarbitone or sodium valproate.

Legal Category: POM

Package Quantities: Blister strips of 10 in cartons of 100.

Product Licence Number: PL 4425/0098

NHS Price: £46.00

Date of Preparation: November 1990.

You must refer to the full prescribing information before administering Sabril. Further information including full product data sheet is available from the Licence Holder: Merrell Dow Pharmaceuticals Ltd, Lakeside House, Stockley Park, Uxbridge, Middlesex, UB11 1BE

Reference:

1. Livingston J *et al* (1989) Br J Clin Pharm 27 (Suppl 1): 1095-1125

JOB NO: SAB 0691



TRADEMARKS: Sabril, Merrell • Dow.

**MERRELL
DOW**

ABC OF CHILD ABUSE

BMJ

EDITED BY ROY MEADOW

Cruelty to children is common; every week at least four children in Britain die as a result of abuse or neglect, and in England alone nearly 40 000 children are listed on child protection ("at risk") registers. The *ABC of Child Abuse* gives clear guidance on how to recognise child abuse—including the more recently identified forms such as sexual and emotional abuse and factitious illnesses—and on what to do when you suspect or know that it is occurring.

Edited by Professor Roy Meadow, head of the department of paediatrics and child health, St James's University Hospital, Leeds, the book has contributions from paediatricians, child psychiatrists, a police surgeon, a social worker, a lawyer, and a victim. It should be read by everyone concerned with the care of children.

Inland £10.95; Abroad £13.00

BMA members:

Inland £9.95; Abroad £12.00

including postage by air abroad

**Please enclose payment with order
or send us full details of your ACCESS,
MASTERCARD or AMERICAN EXPRESS
credit card.**

ORDER FROM British Medical Journal, PO Box 295, London WC1H 9TE or any leading medical bookseller

While you're trying to make it better, make it bearable.



Cancer patients have enough to cope with without the nausea and vomiting caused by therapy which, in some individuals, is severe enough to cause them to refuse further life saving treatment.

Now, Zofran from Glaxo makes it possible to control the problem without adding to the list of unpleasant side effects experienced by these patients.

Zofran effectively treats nausea and vomiting induced by cancer chemotherapy and radiotherapy.^{1,2,3} Yet there is no evidence of extra-pyramidal side effects, little risk of unwanted sedation and no reported drug interactions.^{3,4}


The recommended follow-up dosage is simply 8mg orally t.d.s., allowing most patients to be managed at home.

When patients undergoing cancer therapy need all the help they can get, Zofran helps make the treatment easier to bear.

Zofran

ondansetron ▼

Prescribing Information: Uses Nausea and vomiting due to chemotherapy or radiotherapy. **Dosage** *Highly emetogenic chemotherapy:* 8mg i.v. infusion or slow injection before chemotherapy (plus infusion of 1mg/hr for up to 24 hours after chemotherapy or two further doses 4 hours or more apart). On subsequent days 8mg orally eight-hourly for up to 5 days. *Less emetogenic chemotherapy:* Either 8mg intravenously by slow injection or infusion or 8mg orally one to two hours before chemotherapy, followed by 8mg orally eight-hourly for up to 5 days. *Radiotherapy:* 8mg orally every eight hours starting one to two hours before radiotherapy (see data sheet). **Contra-indications** Hypersensitivity to components. **Precautions** Pregnancy or lactation. **Side effects** Headache, constipation, a warm or flushing sensation in the head or epigastrium. Occasional transient rises in aminotransferases. Rare, immediate hypersensitivity reactions (see data sheet). **Presentations** Zofran Injection

ampoules containing 4mg ondansetron in 2ml aqueous solution or 8mg ondansetron in 4ml aqueous solution (Product licence number 0004/0375, 8mg x 5 ampoules £75; 4mg x 5 ampoules £52.50). Zofran 4mg Tablets each containing 4mg ondansetron (Product licence number 0004/0376, 4mg x 100 tablets £625). Zofran 8mg Tablets each containing 8mg ondansetron (Product licence number 0004/0377, 8mg x 30 tablets £270). **Product licence holder** Glaxo Operations U.K. Limited, Greenford, Middlesex UB6 0HE. Zofran is a Glaxo trade mark. Further information is available on request from: Glaxo Laboratories Limited, Stockley Park West, Uxbridge, Middlesex UB11 1BT Tel: 081-990 9444. **References** 1. Priestman TJ, Roberts JT, Lucraft H, *et al.* *Clin Oncol* 1990; 2: 71-75. 2. Schmoll H-J. *Eur J Cancer Clin Oncol* 1989; 25(Suppl. 1): S35-S39. 3. Marty M. *Eur J Cancer Clin Oncol* 1989; 25(Suppl. 1): S41-S45. 4. Smith RN. *Eur J Clin Oncol* 1989; 25(Suppl. 1): S47-S50. 

MONATS **KINDER** SCHRIFT **HEILKUNDE**

139. Band Heft 8
August 1991

Organ der
Deutschen Gesellschaft
für Kinderheilkunde

Thema des Monats

Umweltmedizin

Editorial 433

N. Krüger, H. Helge,
D. Neubert

Bedeutung von
PCDDs/PCDFs („Dioxinen“)
in der Pädiatrie 434

M. Teufel, I. Böhn,
K. H. Niessen
Belastung unserer Kinder
mit Pestiziden, PCB
und potentiell kritischen
Anionen 442

Pädiatrie aktuell

Einfluß der Behandlung auf
das Längenwachstum von
Patienten mit Phosphat-
diabetes

Spätfolgen der Broncho-
pulmonalen Dysplasie 450

Was hat das Kind?

Trainingsprogramm für die
Weiterbildung zum Kinder-
arzt 451

Klinik und Forschung

K. Bauer, M. Götz,
A. Roithmaier, A. Pröhl,
G. Bovermann, H. Versmold
Postnatale Gewichts-
abnahme beatmeter Früh-
geborener unter 1500 g:
Bedeutung des renalen und
extrarenalen Flüssig-
keitsverlusts 452

B. Schlüter, G. G. Aguigah,
G. E. Bürk, W. Horstmann,
W. Amler
Herpes-simplex-Enzephalitis
im Kindesalter 457

M. Dunitz, P. J. Z. Scheer
Diagnostik und Therapie der
frühen Mutter-Kind-Störung,
die sogenannte Gedeih-
störung des Säuglings 465

R. Abderhalden, M. Amato
Früherkennung der
Hüftgelenkdysplasie im
Neugeborenenalter 471

Der interessante Fall

P. Miledter, I. Kloos, M. Zach
Inspiratorischer Stridor
als einziges Symptom
eines ösophagealen
Fremdkörpers 476

W. Koellen, J. Wentz
Pubertas praecox und
Lachanfalle 479

Wußten Sie schon?

Neues aus Therapie und
Prophylaxe

M. Leichsenring,
H. Bussmann, H. J. Bremer
Malaria prophylaxe bei
Kindern 482

Laudationes

W. Künzer

Prof. Dr. Theodor Luthard
60 Jahre 486

D. Färber

Prof. Dr. Werner Schuster
zum 60. Geburtstag 487

H. W. Rautenburg
Zum 60. Geburtstag von
Prof. Dr. Klaus Menner
488

Was hat das Kind?

Auflösung und
Kommentar des
Trainingsprogramms 489

Neue Bücher

Tagesgeschichte,
Personalia 491

Tagungskalender 492

Abstracts der
87. Jahrestagung der
Deutschen Gesellschaft
für Kinderheilkunde,
1.—4. September 1991
in Frankfurt 493



Springer-Verlag
Berlin Heidelberg New York
London Paris Tokyo
Hong Kong Barcelona Budapest

Annual subscription: DM 298,- plus postage

European Journal of

Pediatrics

Incorporating
Acta Paediatrica Belgica
and
Helvetica Paediatrica Acta

Volume 150 No. 9 1991

The pioneers of pediatric medicine
611

Review

Osteoarticular infections due to *Kingella kingae* in children
M. Lacour, M. Duarte, A. Beutler,
R. Auckenthaler, S. Suter 612

Special article

Paediatric training in the European Community
G. van den Bergh 619

Cardiology

The value of the routine chest roentgenogram in the cardiological evaluation of infants and children. A prospective study
A. M. Temmerman, E. L. Mooyaart,
P. P. Taverne 623

Dermatology

Further delineation of the ichthyosis follicularis, atrichia, and photophobia syndrome
H. Hamm, P. Meinecke, H. Traupe 627

Endocrinology

Pubertal maturation in girls treated for childhood acute leukaemia
F. Maneschi, M. G. Fugardi, G. Corsello,
M. LoCurto 630

The effects of a somatostatin analogue on the metabolism of an infant with Beckwith-Wiedemann syndrome and hyperinsulinaemic hypoglycaemia
W. J. M. Gerver, P. P. C. A. Menheere,
C. Schaap, P. Degraeuwe 634

Gastroenterology/Hepatology

Disorders of oesophageal motility in children with psychomotor retardation and gastro-oesophageal reflux
A. Staiano, S. Cucchiara, E. Del Giudice,
M. R. Andreotti, R. Minella 638

Immunology/Allergology

Salicylate treatment in Kawasaki disease: high dose or low dose?
T. Akagi, H. Kato, O. Inoue, N. Sato 642

Defective activation of the alternative pathway of complement in patients with homozygous C2 deficiency: studies in two unrelated families
R. Schwert, E. Esser, R. A. Seger,
A. Rubinstein, G. Hauptmann, V. Wahn 647

Chronic bilateral dacryo-adenitis in identical twins: a possible incomplete form of Sjögren syndrome
C. Besana, C. Salmaggi, C. Pellegrino,
L. Pierro, S. Vergani, A. Faravelli,
C. Rugarli 652

Medical genetics

A family with severe X-linked arthrogryposis
R. C. M. Hennekam, P. G. Barth,
W. Van Lookeren Campagne,
M. De Visser, K. P. Dingemans 656

Metabolic diseases

Phenylketonuria does not cause cataracts
D. B. Pitt, J. O'Day 661

Vitamin D dependent rickets type II with myelofibrosis and immune dysfunction
M. M. Walka, S. Däumling, H.-B. Hadorn,
K. Kruse, B. H. Belohradsky 665

Chronic metabolic alkalosis in an infant with cystic fibrosis
P. Eigenmann, G. Déléze, H. Kuchler 669

Neonatology

High frequency oscillatory ventilation near resonant frequency of the respiratory system in rabbits with normal and surfactant depleted lungs
A. Schulze, P. Schaller, J. Dinger,
U. Winkler, D. Gmyrek 671

Nephrology/Urology

Testosterone esters advance skeletal maturation more than growth in short boys with chronic renal failure and delayed puberty
M. W. Van Steenberghe, J. M. Wit,
R. A. M. G. Donckerwolcke 676

Neuropediatrics

High dose intravenous gamma-globulin in intractable epilepsy of childhood
A. Etzioni, M. Jaffe, S. Pollack, N. Zelnik,
A. Benderly, Y. Tal 681

Letters to the editors

Organic aciduria in Pearson syndrome
C. Jakobs, P. Danse, A. J. P. Veerman 684

Chronic type B hepatitis and primary hepatocellular carcinoma in children
C. Crivellaro, P. Cadrobbi, G. Perilongo,
F. Rossetti, P. Pontisso, F. Bertolotti 685

Episiotomy and neonatal lidocaine intoxication
C. De Praeter, P. Vanhaesebrouck,
N. De Praeter, P. Govaert, M. Bogaert,
J. Leroy 685

Isolated intention tremor: a sign of metastatic neuroblastoma
P. Lutz, D. Chaigne, J. M. Levy 686

Coffin-Siris syndrome with normal plasma biotinidase activity
D. Bonneau, M. Berthier, D. Oriot,
A. Munnich 687

Reply
A. B. Burlina, W. G. Sherwood 687

First experience with pentamidine inhalation in human immunodeficiency virus-infected children
W. Kreuz, T. Güngör, M. Funk, R. Linde,
S. Ehrenforth, C. Lotz, B. Kornhuber 687

Indexed in *Current Contents*



Springer International

Subscription information

Volume 150 (12 issues) will appear in 1991. Information about obtaining back volumes and microform editions available upon request.

North America. Annual subscription rate: approx. US \$ 1060.00 (single issue price approx. \$ 102.00), including carriage charges. Subscriptions are entered with prepayment only.


Orders should be addressed to:
Springer-Verlag New York Inc.
Service Center Secaucus
44 Hartz Way
Secaucus, NJ 07094, USA
Tel. (201) 348-4033
Telex 023125994
FAX (201) 348-4505

All other countries. Annual subscription rate: DM 1598.00 plus carriage charges; Federal Republic of Germany: DM 27.61 incl. value added tax; all other countries: DM 60.60 ex-

cept for the following countries to which SAL delivery (Surface Airmail Lifted) is mandatory: Japan DM 125.40, India DM 96.60, Australia/New Zealand DM 141.00. Airmail delivery to all other countries is available upon request. Volume price: DM 1598.00, single issue price: DM 159.80 plus carriage charges. Subscriptions can either be placed via a bookdealer or sent directly to:

Springer-Verlag
Heidelberger Platz 3, 1000 Berlin 33, FRG
Tel. (0)30/8207-0, Telex 183319
FAX (0)30/8214091

"Days
to remember
... *all my life*"



Prescribing Information PenMix[®] 30/70 Penfill[®] 100iu/ml (Biphasic Isophane Insulin Injection 30/70), Human Insulin (pyr).

Indications: The treatment of insulin-requiring diabetics.

Dosage and Administration: The dosage is determined by the physician according to the needs of the patient. Given by subcutaneous injection and intended for use in the NovoPen and NovoPen II injection devices only. (See instructions for use of devices). Resuspend before use by agitating up and down.

Contraindications: Hypoglycaemia. **Precautions:** Injections of PenMix 30/70 Penfill should be followed by a meal within 30 minutes of administration. A dosage reduction may be required on transfer from bovine or mixed species insulin. Reduction of early warning symptoms of hypoglycaemia may be seen upon tightening control and has been reported by a few patients on transfer from animal source to human insulin. Beta blockers, MAOIs and alcohol may enhance hypoglycaemic effect of insulin. Corticosteroids, thyroid hormones, oral contraceptives may increase insulin requirements. **Use in pregnancy:** Insulin requirements usually fall during the first trimester and increase during second and third trimester. **Side-effects:** Lipodystrophy, insulin resistance and hyper-sensitivity are rarely reported with human insulin. **Product Licence Number and Basic NHS Price:** PL 4668/0020, 5x1.5ml cartridges £8.10. **Product Licence Holder:** Novo Nordisk A/S, Novo Alle, DK-2880 Bagsvaerd, Denmark. **Sole Distributor:** Parillon Limited, Ashton Road, Harold Hill, Romford, Essex RM3 8UE.

Further information is available on request from: Novo Nordisk Pharmaceuticals Ltd., Novo Nordisk House, Broadfield Park, Brighton Road, Pease Pottage, Crawley, West Sussex RH11 9RT. Telephone: (0293) 613555.

June 1991

* Registered trade mark of Novo Nordisk A/S

Free supplies of NovoPen II available on request
DIAL 100 AND ASK FOR FREEPHONE
NOVO NORDISK INSULIN


Leading the way in diabetes care



For many patients with diabetes, convenience can matter just as much as control.

That is why PenMix 30/70 Penfill is such an appropriate choice for people of all ages.

PenMix 30/70 Penfill lets them get on with enjoying their lives without the fuss and bother of complex in-syringe insulin mixing and with the added convenience of NovoPen[®] II.



PenMix[®] 30/70 PENFILL[®]

Biphasic Isophane Insulin injection.

Human Insulin (pyr)

CONVENIENCE WITH CONTROL
ALL IN ONE EASY STEP